BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the clinical research study is to assess the safety of treating
children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will
assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid
Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence
of disease flare.